Volume : 09, Issue : 03, March – 2022
Title:
16.A REVIEW ON THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Authors :
Pravallika D , Priyanka S K, Rahmath Nisha Z , Dr. Jeevan Kumar B *, Dr. Devaki K , Dr. Ganesh Kumar M , Dr. Kishore Babu M
Abstract :
Osteoporosis, derived from the Greek term “porous bone,” means a systemic bone disease, characterized by micro architectural deterioration, bone loss and density. Decreased bone density is also associated with increased bone density and softening of the bones. This results in increased medical expenditures and morbidity with a decrease in the quality of life of patients. According to the World Health Organization, this is defined as a decrease in bone mass (BMD) of a normal deviation of 2.5 or more below the maximum BMD rate in adults with an equal number of x-ray absorptiometry. The main objective of this article is to guide the causes, risk factors, pathogenesis, prevention, diagnosis, and management of osteoporosis in postmenopausal women. Altering the current screening guidelines for bone density and suggestions for treatment is essential. The choice of treatment depends on the age, presence or absence of fractures, especially in the spine, and the level of mineral bones measured in the spine.
Osteoporosis is a bone disease characterized by bone loss, density, mass, and microarchitectural tissues that lead to bone fractures worldwide. Risk factors are associated with age, sex, hormone deficiency, underlying issues, previous fractures, and medications. The pathophysiology includes different pathways, such as classical, epigenetic, post-transcriptional, gut microbiotas, and stress-mediated signalling. Bone loss occurs without any symptoms. Screening includes both laboratory and instrumental tests such as FRAX score, thyroid dysfunctions, X-ray absorptiometry and ultrasonography. Management includes calcium/vitamin D, bisphosphonates, denosumab, estrogen replacement, and selective estrogen receptor modulators, calcitonin, odanacatib, lasofoxifene, parathyroid, and hormone-related protein analogs, strontium ranelate for a better treatment strategy approach to improve patient health.
Cite This Article:
Please cite this article in press Jeevan Kumar B et al, A Review On The Management Of Postmenopausal Osteoporosis., Indo Am. J. P. Sci, 2022; 09(3),.
Number of Downloads : 10
References:
1. Pavone V, Testa G, Giardina SMC, Vescio A, Restivo DA, Sessa G. Pharmacological therapy of osteoporosis: A systematic current review of literature. Front Pharmacol. 2017;8:803.
2. Learn what osteoporosis is and what it’s caused by [Internet]. Nof.org. 2015 [cited 2021 Sep 21]. Available from: http://www.nof.org/patients/what-is-osteoporosis/.
3. Mackenzie Moritz et al. Updates in the treatment of postmenopausal osteoporosis [Internet]. Uspharmacist.com. 2019 [cited 2021 Sep 21]. Available from: https://www.uspharmacist.com/article/updates-in-the-treatment-of-postmenopausal-osteoporosis
4. Mohamed AS, Khalifa AI, Abotaleb AA-M, Eldesoky NA-R. Comparative study between periostin and osteocalcin as biomarkers for osteoporosis and fracture risk in Egyptian postmenopausal women. Int J Pharm Pharm Sci. 2020;17–22.
5. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–622.
6. About NOF [Internet]. Nof.org. 2016 [cited 2021 Sep 21]. Available from: http://www.nof.org/about-us/about-nof/.
7. Osteoporosis and Menopause [Internet]. Webmd.com. [cited 2021 Sep 21]. Available from: https://www.webmd.com/menopause/guide/osteoporosis-menopause
8. Rossi LMM, Copes RM, Dal Osto LC, Flores C, Comim FV, Premaor MO. Factors related with osteoporosis treatment in postmenopausal women. Medicine (Baltimore). 2018;97(28):e11524.
9. Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ 3rd. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int. 2012;23(3):811–20.
10. Morrison A, Fan T, Sen SS, Weisenfluh L. Epidemiology of falls and osteoporotic fractures: a systematic review. Clinicoecon Outcomes Res. 2013;5:9–18.
11. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society: 2010 Position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54
12. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41.
13. Amber R, Erin Z, Tamera P. Osteoporosis: Bisphosphonate therapy in postmenopausal women. J Fam Med Dis Prev. 2019 [cited 2021 Sep 21];5(4).
14. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359(9322):2018–26.
15. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.
16. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society: 2010 Position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54; quiz 55–6.
17. Kwun S, Laufgraben MJ, Gopalakrishnan G. Prevention and treatment of postmenopausal osteoporosis. Obstet Gynaecol. 2012;14(4):251–6.
18. Kristie N, et al. Osteoporosis: A review of Treatment Options.2018;43(2):92-104.
19. WebMD – Better information. Better health [Internet]. Webmd.com. [cited 2021 Sep 21]. Available from: https://www.webmd.com/osteoporosis/understanding-osteoporosis-basics.
20. 19Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE. Diagnosis and management of osteoporosis. Am Fam Physician. 2015;92(4):261–8.
21. Osteoporosis: Treatment, symptoms, causes, medications, exercise & diet [Internet]. Medicinenet.com. [cited 2021 Sep 21]. Available from: https://www.medicinenet.com/osteoporosis/article.htm
22. MacGill M. Osteoporosis: Risk factors, diagnosis, and treatment [Internet]. Medicalnewstoday.com. 2019 [cited 2021 Sep 21]. Available from: https://www.medicalnewstoday.com/articles/155646
23. Ateia YA, Al-edanni MS, Al-qurtas MI. Impact of metformin and serratiopeptidase in obese patients with knee osteoarthritis. Int J Pharm Pharm Sci. 2018;10(2):37.
24. Runhaar J, Koes BW, Clockaerts S, Bierma-Zeinstra SM. A systematic review on the changed biomechanics of lower extremities in obese individuals: a possible role in the development of osteoarthritis. Obes Rev 2011;12:1071–82.
25. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573–7.
26. Velasquez MT, Katz JD. Osteoarthritis: another component of metabolic syndrome? Metab Syndr Relat Disord 2010;8:295–305
27. Matt. Postmenopausal osteoporosis: A mini review [Internet]. Emjreviews.com. 2019 [cited 2021 Sep 21]. Available from: https://www.emjreviews.com/rheumatology/article/postmenopausal-osteoporosis-a-mini-review/
28. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–70.
29. Schweser KM, Crist BD. Osteoporosis: a discussion on the past 5 years. Curr Rev Musculoskelet Med. 2017;10(2):265–74.
30. Gillespie CW, Morin PE. Trends and disparities in osteoporosis screening among women in the United States, 2008-2014. Am J Med. 2017;130(3):306–16.
31. Zheng J, Mao X, Ling J, He Q, Quan J, Jiang H. Association between serum level of magnesium and postmenopausal osteoporosis: a meta-analysis. Biol Trace Elem Res. 2014;159(1–3):8–14.
32. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.
33. Nayak S, Greenspan SL. Cost-effectiveness of osteoporosis screening strategies for men. J Bone Miner Res. 2016;31(6):1189–99.
34. Garg MK, Kharb S. Dual energy X-ray absorptiometry: Pitfalls in measurement and interpretation of bone mineral density. Indian J Endocrinol Metab. 2013;17(2):203–10.
35. Pisani P, Renna MD, Conversano F, Casciaro E, Muratore M, Quarta E, et al. Screening and early diagnosis of osteoporosis through X-ray and ultrasound based techniques. World J Radiol. 2013;5(11):398–410.
36. Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV, Epidemiology and Quality of Life Working Group of IOF. Worldwide uptake of FRAX. Arch Osteoporos. 2014;9(1):166.
37. Høiberg MP, Rubin KH, Hermann AP, Brixen K, Abrahamsen B. Diagnostic devices for osteoporosis in the general population: A systematic review. Bone. 2016;92:58–69.
38. Karjalainen JP, Riekkinen O, Töyräs J, Jurvelin JS, Kröger H. New method for point-of-care osteoporosis screening and diagnostics. Osteoporos Int. 2016;27(3):971–7.
39. Testa G PV, Lucenti L AF. The importance of a correct diet in preventing osteoporosis. J Osteoporos Phys Act [Internet]. 2015;03(03). Available from: https://www.longdom.org/open-access/the-importance-of-a-correct-diet-in-preventing-osteoporosis-2329-9509-1000160.pdf
40. Fukumoto S, Matsumoto T. Recent advances in the management of osteoporosis. F1000Res. 2017;6:625.
41. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.
42. Hiligsmann M, Neuprez A, Buckinx F, Locquet M, Reginster J-Y. A scoping review of the public health impact of vitamin D-fortified dairy products for fracture prevention. Arch Osteoporos. 2017;12(1):57.
43. Pazianas M, Abrahamsen B. Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least? Ann N Y Acad Sci. 2016;1376(1):5–13.
44. Takeuchi T, Tanaka Y et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75(6):983–90.
45. Suzuki T, Nakamura Y, Kato H. Changes of bone-related minerals during denosumab administration in post-menopausal osteoporotic patients. Nutrients [Internet]. 2017;9(8). Available from: http://dx.doi.org/10.3390/nu9080871
46. Bonani M, Frey D, de Rougemont O, Mueller NJ, Mueller TF, Graf N, et al. Infections in DE Novo kidney transplant recipients treated with the RANKL inhibitor denosumab. Transplantation. 2017;101(9):2139–45.
47. Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: A randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab. 2016;101(9):3497–505.
48. Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B. New horizons in treatment of osteoporosis. Daru. 2017;25(1):2.
49. Lobo RA, Pickar JH, Stevenson JC, Mack WJ, Hodis HN. Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 2016;254:282–90.
50. Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians, Barry MJ, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–39.
51. Börjesson AE, Farman HH, Movérare-Skrtic S, Engdahl C, Antal MC, Koskela A, et al. SERMs have substance-specific effects on bone, and these effects are mediated via ERαAF-1 in female mice. Am J Physiol Endocrinol Metab. 2016;310(11):E912-8.
52. Bandeira L, Lewiecki EM, Bilezikian JP. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2016;12(6):681–9.
53. Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, et al. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Bone. 2016;91:122–9.
54. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–622.
55. Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS), Italian Society of Rheumatology (SIR), Varenna M, Bertoldo F, Di Monaco M, Giusti A, et al. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo. 2013;65(4):143–66.
56. Das S, Crockett JC. Osteoporosis – a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013;7:435–48.
57. Komm BS, Morgenstern D, A Yamamoto L, Jenkins SN. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Expert Rev Clin Pharmacol. 2015;8(6):769–84.
58. O’Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2006;(3):CD005326.